Eupraxia Pharmaceuticals is trading at $8.49, up 5.99% in pre-market; no company-specific announcement explaining the September 28 gain was identified.
- The latest identified company news was its September 8 transfer to the Nasdaq Global Select Market. A September 24 report said Wedbush initiated coverage with an Outperform rating and a $17 target; neither establishes the cause of the move.
- Broader market sentiment is negative, with major indices lower, so it does not explain the stock’s opposite-direction move. No volume or activity data was provided.